Ann: Preliminary PAT-DX1 pharmacokinetics, page-16

It looks both PAT-DX1 and PAT-DX1-NP work well against TNBC, according to the info from the anns.

Patrys has also completed the first animal study using PAT-DX1, in a mouse model of triple negative breast cancer. These studies have shown signals of efficacy and will act as guidance for dosing and route of administration for PAT-DX1 in future animal studies.
"... These results, combined with similar signals of efficacy in a mouse model of aggressive breast cancer, affirm that the humanized version of 3E10, PAT-DX1, is an outstanding candidate to progress towards the clinic,” said Dr. James Campbell ...
- PAT-DX1 Active in Pre-clinical Cancer Models, 14 Sep 2017

Studies performed in the laboratories of Dr James Hansen and Dr Jiangbing Zhou at Yale University found that mice with xenograft triple negative breast cancer tumors showed significantly higher localization of PAT-DX1-NP at the tumor sites when compared with unconjugated nanoparticles.
- PAT-DX1 Targets Delivery of Nanoparticles to Breast Cancer Tumors in Animal Model, 29 Jan 2018

Drs. James Hansen and Jiangbing Zhou of the Yale School of Medicine have confirmed that as a single agent PAT-DX1 localizes into xenograft triple negative breast cancer (TNBC) tumors in mice.
“We are very pleased that PAT-DX1 is confirmed to target TNBC tumors, with clear tumor penetration 8 hours after administration. These results provide a foundation for more extensive studies of the effect of PAT-DX1 on TNBC, both as a single agent and in combination with various drugs such as DNA-damaging chemotherapies and PARP inhibitors,” said Dr. James Campbell ...
- Preliminary PAT-DX1 pharmacokinetics, 5 Jul 2018